MedTrace Logo

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

NCT06311578 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.

Conditions

  • Neoplasms

Interventions

DRUG

JNJ-87704916

JNJ-87704916 will be administered as an intratumoral injection.

DRUG

Cetrelimab

Cetrelimab will be administered.

DRUG

Standard of Care PD(L)-1

Frontline anti-PD(L)-1 antibody therapy will be administered as standard of care treatment.

Sponsors & Collaborators

  • Johnson & Johnson Enterprise Innovation Inc.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Enterprise Innovation Inc Clinical Trial · Johnson & Johnson Enterprise Innovation Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-10
Primary Completion
2028-11-08
Completion
2032-08-26
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06311578 on ClinicalTrials.gov